PATRYS LIMITED - Announcements

Market Cap $18.51M Add to my watchlist

Healthcare Biotechnology

Patrys Limited is an Australia-based company, which is focused on the development of its... Patrys Limited is an Australia-based company, which is focused on the development of its deoxymab platform of cell-penetrating antibodies as therapies for a range of different cancers. The Company's deoxymab platform is based on the deoxymab 3E10 antibody that was identified as an autoantibody in a mouse model of the human disease systemic lupus erythematosus. It has developed two humanized forms of deoxymab 3E10, both of which have improved activity over the original deoxymab 3E10 antibody: PAT-DX1, which is a dimer (two joined subunits) of the short chain from the binding domain of deoxymab 3E10, and PAT-DX3, which is a full-sized Immunoglobulin G antibody. Deoxymabs, such as PAT-DX1 and PAT-DX3, can be used to target nanoparticles carrying a payload of anti-cancer drugs specifically to tumors. Its PAT-DX1- nanoparticles (NP) pipeline involves using its PAT-DX1 to develop a new drug based on the targeted delivery of NP carrying therapeutic payloads to the inside of cancer cells.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Announcements

Filter Results

All Price Sensitive Only

Filters [Clear]

Price Sensitive: Yes

PAB	Positive preclinical data for deoxymabs in vasculitis	PRICE SENSITIVE	09/04/24	299.83KB	Share
PAB	Appendix 4D - Half Year Accounts - 31 December 2023	PRICE SENSITIVE	23/02/24	457.19KB	Share
PAB	Appendix 4C - Quarterly - 31 December 2023	PRICE SENSITIVE	23/01/24	517.63KB	Share
PAB	GMP Production of PAT-DX1 Next Quarter	PRICE SENSITIVE	13/12/23	217.51KB	Share
PAB	Patrys Receives R&D Tax Incentive Refund	PRICE SENSITIVE	08/11/23	217KB	Share
PAB	Appendix 4C - Quarterly - 30 September 2023	PRICE SENSITIVE	20/10/23	487.36KB	Share
PAB	Appendix 4E and 2023 Annual Report	PRICE SENSITIVE	28/08/23	11.45MB	Share
PAB	Appendix 4C - Quarterly - 30 June 2023	PRICE SENSITIVE	26/07/23	532.25KB	Share
PAB	PAT-DX1 GLP toxicology reports received	PRICE SENSITIVE	24/05/23	218.67KB	Share
PAB	Appendix 4C - Quarterly - 31 March 2023	PRICE SENSITIVE	24/04/23	522.86KB	Share
PAB	Two new deoxymab patents granted in the USA	PRICE SENSITIVE	17/04/23	293.01KB	Share
PAB	Updated guidance for PAT-DX1 phase 1 clinical study	PRICE SENSITIVE	31/03/23	246KB	Share
PAB	New PAT-DX3 data demonstrates synthetic lethality	PRICE SENSITIVE	14/03/23	366.75KB	Share
PAB	Appendix 4D - Half Year Accounts - 31 December 2022	PRICE SENSITIVE	24/02/23	1.27MB	Share
PAB	Appendix 4C - Quarterly - 31 December 2022	PRICE SENSITIVE	31/01/23	566.94KB	Share
PAB	Patrys Receives R&D Tax Incentive Refund	PRICE SENSITIVE	30/01/23	216.54KB	Share
PAB	Response to ASX Price Query	PRICE SENSITIVE	14/12/22	412.59KB	Share
PAB	Appendix 4C - Quarterly - 30 September 2022	PRICE SENSITIVE	28/10/22	471.72KB	Share
PAB	PAT DX3 Crosses Blood Brain Barrier in Healthy Animals	PRICE SENSITIVE	17/10/22	194.16KB	Share
PAB	Appendix 4E and 2022 Annual Report	PRICE SENSITIVE	30/08/22	12.04MB	Share
PAB	PAT-DX1 From Engineering Run Meets all Specification Tests	PRICE SENSITIVE	30/08/22	258.5KB	Share
PAB	New Research Grant For Deoxymabs in Metastatic Breast Cancer	PRICE SENSITIVE	26/08/22	223.85KB	Share
PAB	PAT-DX1/Radiation Combination Improves Brain Cancer Survival	PRICE SENSITIVE	10/08/22	446.28KB	Share
PAB	Appendix 4C - Quarterly - 30 June 2022	PRICE SENSITIVE	28/07/22	567.83KB	Share
PAB	PAT-DX1 Engineering Run Successfully Completed	PRICE SENSITIVE	04/07/22	220.68KB	Share
PAB	New Mechanism By Which PAT-DX1 May Reduce Cancer Metastasis	PRICE SENSITIVE	14/06/22	295.27KB	Share
PAB	CBCF funding to support deoxymab brain cancer development	PRICE SENSITIVE	03/06/22	308.87KB	Share
PAB	Appendix 4C - Quarterly - 31 March 2022	PRICE SENSITIVE	28/04/22	504.72KB	Share
PAB	Stable Cell Line for Production of PAT-DX3 Established	PRICE SENSITIVE	28/02/22	188.9KB	Share
PAB	Appendix 4D - Half Year Accounts - 31 December 2021	PRICE SENSITIVE	24/02/22	1.15MB	Share
PAB	Appendix 4C - Quarterly - 31 December 2021	PRICE SENSITIVE	31/01/22	311.35KB	Share
PAB	Patrys Receives R&D Tax Incentive Refund	PRICE SENSITIVE	24/01/22	161.41KB	Share
PAB	PAT-DX1 engineering update	PRICE SENSITIVE	24/01/22	145.66KB	Share
PAB	Rights Issue Results and Shortfall Notification	PRICE SENSITIVE	02/12/21	192.35KB	Share
PAB	Rights Issue Offer Document	PRICE SENSITIVE	09/11/21	356.15KB	Share
PAB	$7.8M Capital Raising	PRICE SENSITIVE	01/11/21	221.31KB	Share
PAB	Trading Halt	PRICE SENSITIVE	28/10/21	252.57KB	Share
PAB	Appendix 4C - Quarterly - 30 September 2021	PRICE SENSITIVE	20/10/21	399.01KB	Share
PAB	Patrys proof of concept ADC significantly increases survival	PRICE SENSITIVE	18/10/21	268.44KB	Share
PAB	PAT-DX3 proof of concept as potential ADC targeting antibody	PRICE SENSITIVE	15/09/21	302.49KB	Share
PAB	Appendix 4E and 2021 Annual Report	PRICE SENSITIVE	25/08/21	3.39MB	Share
PAB	Market Update - PAT-DX1 Clinical Trial Preparation	PRICE SENSITIVE	03/08/21	146.08KB	Share
PAB	Appendix 4C - Quarterly - 30 June 2021	PRICE SENSITIVE	29/07/21	345.35KB	Share
PAB	PAT-DX1 Improves Survival in Model of Pancreatic Cancer	PRICE SENSITIVE	26/07/21	202.8KB	Share
PAB	Full size deoxymab PAT-DX3 crosses the blood brain barrier	PRICE SENSITIVE	12/07/21	164.63KB	Share
PAB	Response to ASX Query	PRICE SENSITIVE	24/06/21	282.28KB	Share
PAB	Paper highlights PAT-DX1 as potential brain cancer treatment	PRICE SENSITIVE	16/06/21	326.04KB	Share
PAB	Patrys receives R&D Tax Incentive refund	PRICE SENSITIVE	10/06/21	161.19KB	Share
PAB	Appendix 4C - Quarterly - 31 March 2021	PRICE SENSITIVE	28/04/21	381.84KB	Share
PAB	New United States patent granted for Patrys' deoxymab assets	PRICE SENSITIVE	31/03/21	194.5KB	Share
PAB	Appendix 4D - Half Year Accounts - 31 December 2020	PRICE SENSITIVE	19/02/21	748.01KB	Share
PAB	Patrys Successfully Establishes PAT-DX1 Stable Cell Line	PRICE SENSITIVE	10/02/21	125.16KB	Share
PAB	Appendix 4C - Quarterly - 31 December 2020	PRICE SENSITIVE	28/01/21	203.68KB	Share
PAB	Entitlement Offer Prospectus	PRICE SENSITIVE	09/11/20	390.61KB	Share
PAB	$7.3M Capital Raising	PRICE SENSITIVE	09/11/20	147.87KB	Share
PAB	Investor Presentation - November 2020 - Updated	PRICE SENSITIVE	05/11/20	11.32MB	Share
PAB	Investor Presentation - November 2020	PRICE SENSITIVE	05/11/20	1.46MB	Share
PAB	Trading Halt	PRICE SENSITIVE	05/11/20	200.12KB	Share
PAB	Appendix 4C - Quarterly - 30 September 2020	PRICE SENSITIVE	26/10/20	237.83KB	Share
PAB	Response to ASX Price Query	PRICE SENSITIVE	23/10/20	225.68KB	Share
PAB	First patent granted for Deoxymab-nanoparticles	PRICE SENSITIVE	06/10/20	231.93KB	Share
PAB	Patrys adds full human antibody to Deoxymab portfolio	PRICE SENSITIVE	28/09/20	276.67KB	Share
PAB	Response to ASX Price Query	PRICE SENSITIVE	15/09/20	224.67KB	Share
PAB	Appendix 4E and 2020 Annual Report	PRICE SENSITIVE	25/08/20	1.13MB	Share
PAB	Appendix 4C - Quarterly - 30 June 2020	PRICE SENSITIVE	30/07/20	237.92KB	Share
PAB	Entitlement Offer Prospectus	PRICE SENSITIVE	22/06/20	408.76KB	Share
PAB	$4.29 Million Fully Underwritten Rights Issue	PRICE SENSITIVE	22/06/20	138.68KB	Share
PAB	Investor Presentation - June 2020	PRICE SENSITIVE	18/06/20	5.14MB	Share
PAB	Trading Halt	PRICE SENSITIVE	18/06/20	275.21KB	Share
PAB	Appendix 4C - Quarterly - 31 March 2020	PRICE SENSITIVE	27/04/20	223.23KB	Share
PAB	PAT-DX1 mechanism for crossing blood brain barrier confirmed	PRICE SENSITIVE	16/03/20	258.28KB	Share
PAB	PAT-DX1-NP crosses BBB and targets tumours	PRICE SENSITIVE	02/03/20	229.63KB	Share
PAB	Appendix 4D - Half Year Accounts - 31 December 2019	PRICE SENSITIVE	24/02/20	585.47KB	Share
PAB	Appendix 4C - Quarterly - 31 December 2019	PRICE SENSITIVE	30/01/20	269.8KB	Share
PAB	Patrys Receives R&D Tax Incentive Refund	PRICE SENSITIVE	07/11/19	146.68KB	Share
PAB	Appendix 4C - Quarterly - 30 September 2019	PRICE SENSITIVE	29/10/19	278.62KB	Share
PAB	Appendix 4E and 2019 Annual Report	PRICE SENSITIVE	23/08/19	1.1MB	Share
PAB	Appendix 4C - Quarterly - 30 June 2019	PRICE SENSITIVE	30/07/19	173.33KB	Share
PAB	PAT-DX1 significantly improves survival in aggressive GBM	PRICE SENSITIVE	22/07/19	288.63KB	Share
PAB	Europe grants patent for Deoxymab 3E10	PRICE SENSITIVE	17/07/19	615.05KB	Share
PAB	PAT-DX1 Reduces Brain Metastases, Enhances Radiation Therapy	PRICE SENSITIVE	30/05/19	254.91KB	Share
PAB	Appendix 4C - Quarterly - 31 March 2019	PRICE SENSITIVE	24/04/19	235.56KB	Share
PAB	Market Update	PRICE SENSITIVE	29/03/19	243.59KB	Share
PAB	Appendix 4D - Half Year Accounts - 31 December 2018	PRICE SENSITIVE	20/02/19	487.29KB	Share
PAB	Appendix 4C - Quarterly - 31 December 2018	PRICE SENSITIVE	30/01/19	279.89KB	Share
PAB	Patrys Receives R&D Tax Incentive Refund	PRICE SENSITIVE	08/01/19	108.29KB	Share
PAB	PAT-DX1 Suppresses Breast Cancer Brain Metastases	PRICE SENSITIVE	20/12/18	248.11KB	Share
PAB	Appendix 4C - Quarterly - 30 September 2018	PRICE SENSITIVE	31/10/18	233.2KB	Share
PAB	Settlement of Manufacturing Claims	PRICE SENSITIVE	25/10/18	102.79KB	Share
PAB	PAT-DX1 Clinical Target Indications Confirmed	PRICE SENSITIVE	04/10/18	252.8KB	Share
PAB	Patrys and WEHI Awarded Grant	PRICE SENSITIVE	28/08/18	252.24KB	Share
PAB	Appendix 4E and 2018 Annual Report	PRICE SENSITIVE	24/08/18	1.1MB	Share
PAB	Patent Granted for Pre-clinical IgM Candidate PAT-LM1	PRICE SENSITIVE	01/08/18	710.34KB	Share
PAB	Appendix 4C - Quarterly - 30 June 2018	PRICE SENSITIVE	26/07/18	235.01KB	Share
PAB	Preliminary PAT-DX1 pharmacokinetics	PRICE SENSITIVE	05/07/18	165.25KB	Share
PAB	China and Japan both grant patents for Deoxymab 3E10	PRICE SENSITIVE	03/07/18	140.91KB	Share
PAB	PAT-DX1 Targets and Kills Brain Cancer Stem Cells	PRICE SENSITIVE	31/05/18	142.76KB	Share
PAB	Patrys Increases Capital Raising to $4.6 million	PRICE SENSITIVE	21/05/18	100.89KB	Share
PAB	New Pre-Clinical Collaboration on PAT-DX1	PRICE SENSITIVE	17/05/18	138.9KB	Share
PAB	Patrys Completes $3.5M Placement	PRICE SENSITIVE	16/05/18	99.71KB	Share

PAB Positive preclinical data for deoxymabs in vasculitis
09/04/24	PRICE SENSITIVE	299.83KB	Share
PAB Appendix 4D - Half Year Accounts - 31 December 2023
23/02/24	PRICE SENSITIVE	457.19KB	Share
PAB Appendix 4C - Quarterly - 31 December 2023
23/01/24	PRICE SENSITIVE	517.63KB	Share
PAB GMP Production of PAT-DX1 Next Quarter
13/12/23	PRICE SENSITIVE	217.51KB	Share
PAB Patrys Receives R&D Tax Incentive Refund
08/11/23	PRICE SENSITIVE	217KB	Share
PAB Appendix 4C - Quarterly - 30 September 2023
20/10/23	PRICE SENSITIVE	487.36KB	Share
PAB Appendix 4E and 2023 Annual Report
28/08/23	PRICE SENSITIVE	11.45MB	Share
PAB Appendix 4C - Quarterly - 30 June 2023
26/07/23	PRICE SENSITIVE	532.25KB	Share
PAB PAT-DX1 GLP toxicology reports received
24/05/23	PRICE SENSITIVE	218.67KB	Share
PAB Appendix 4C - Quarterly - 31 March 2023
24/04/23	PRICE SENSITIVE	522.86KB	Share
PAB Two new deoxymab patents granted in the USA
17/04/23	PRICE SENSITIVE	293.01KB	Share
PAB Updated guidance for PAT-DX1 phase 1 clinical study
31/03/23	PRICE SENSITIVE	246KB	Share
PAB New PAT-DX3 data demonstrates synthetic lethality
14/03/23	PRICE SENSITIVE	366.75KB	Share
PAB Appendix 4D - Half Year Accounts - 31 December 2022
24/02/23	PRICE SENSITIVE	1.27MB	Share
PAB Appendix 4C - Quarterly - 31 December 2022
31/01/23	PRICE SENSITIVE	566.94KB	Share
PAB Patrys Receives R&D Tax Incentive Refund
30/01/23	PRICE SENSITIVE	216.54KB	Share
PAB Response to ASX Price Query
14/12/22	PRICE SENSITIVE	412.59KB	Share
PAB Appendix 4C - Quarterly - 30 September 2022
28/10/22	PRICE SENSITIVE	471.72KB	Share
PAB PAT DX3 Crosses Blood Brain Barrier in Healthy Animals
17/10/22	PRICE SENSITIVE	194.16KB	Share
PAB Appendix 4E and 2022 Annual Report
30/08/22	PRICE SENSITIVE	12.04MB	Share
PAB PAT-DX1 From Engineering Run Meets all Specification Tests
30/08/22	PRICE SENSITIVE	258.5KB	Share
PAB New Research Grant For Deoxymabs in Metastatic Breast Cancer
26/08/22	PRICE SENSITIVE	223.85KB	Share
PAB PAT-DX1/Radiation Combination Improves Brain Cancer Survival
10/08/22	PRICE SENSITIVE	446.28KB	Share
PAB Appendix 4C - Quarterly - 30 June 2022
28/07/22	PRICE SENSITIVE	567.83KB	Share
PAB PAT-DX1 Engineering Run Successfully Completed
04/07/22	PRICE SENSITIVE	220.68KB	Share
PAB New Mechanism By Which PAT-DX1 May Reduce Cancer Metastasis
14/06/22	PRICE SENSITIVE	295.27KB	Share
PAB CBCF funding to support deoxymab brain cancer development
03/06/22	PRICE SENSITIVE	308.87KB	Share
PAB Appendix 4C - Quarterly - 31 March 2022
28/04/22	PRICE SENSITIVE	504.72KB	Share
PAB Stable Cell Line for Production of PAT-DX3 Established
28/02/22	PRICE SENSITIVE	188.9KB	Share
PAB Appendix 4D - Half Year Accounts - 31 December 2021
24/02/22	PRICE SENSITIVE	1.15MB	Share
PAB Appendix 4C - Quarterly - 31 December 2021
31/01/22	PRICE SENSITIVE	311.35KB	Share
PAB Patrys Receives R&D Tax Incentive Refund
24/01/22	PRICE SENSITIVE	161.41KB	Share
PAB PAT-DX1 engineering update
24/01/22	PRICE SENSITIVE	145.66KB	Share
PAB Rights Issue Results and Shortfall Notification
02/12/21	PRICE SENSITIVE	192.35KB	Share
PAB Rights Issue Offer Document
09/11/21	PRICE SENSITIVE	356.15KB	Share
PAB $7.8M Capital Raising
01/11/21	PRICE SENSITIVE	221.31KB	Share
PAB Trading Halt
28/10/21	PRICE SENSITIVE	252.57KB	Share
PAB Appendix 4C - Quarterly - 30 September 2021
20/10/21	PRICE SENSITIVE	399.01KB	Share
PAB Patrys proof of concept ADC significantly increases survival
18/10/21	PRICE SENSITIVE	268.44KB	Share
PAB PAT-DX3 proof of concept as potential ADC targeting antibody
15/09/21	PRICE SENSITIVE	302.49KB	Share
PAB Appendix 4E and 2021 Annual Report
25/08/21	PRICE SENSITIVE	3.39MB	Share
PAB Market Update - PAT-DX1 Clinical Trial Preparation
03/08/21	PRICE SENSITIVE	146.08KB	Share
PAB Appendix 4C - Quarterly - 30 June 2021
29/07/21	PRICE SENSITIVE	345.35KB	Share
PAB PAT-DX1 Improves Survival in Model of Pancreatic Cancer
26/07/21	PRICE SENSITIVE	202.8KB	Share
PAB Full size deoxymab PAT-DX3 crosses the blood brain barrier
12/07/21	PRICE SENSITIVE	164.63KB	Share
PAB Response to ASX Query
24/06/21	PRICE SENSITIVE	282.28KB	Share
PAB Paper highlights PAT-DX1 as potential brain cancer treatment
16/06/21	PRICE SENSITIVE	326.04KB	Share
PAB Patrys receives R&D Tax Incentive refund
10/06/21	PRICE SENSITIVE	161.19KB	Share
PAB Appendix 4C - Quarterly - 31 March 2021
28/04/21	PRICE SENSITIVE	381.84KB	Share
PAB New United States patent granted for Patrys' deoxymab assets
31/03/21	PRICE SENSITIVE	194.5KB	Share
PAB Appendix 4D - Half Year Accounts - 31 December 2020
19/02/21	PRICE SENSITIVE	748.01KB	Share
PAB Patrys Successfully Establishes PAT-DX1 Stable Cell Line
10/02/21	PRICE SENSITIVE	125.16KB	Share
PAB Appendix 4C - Quarterly - 31 December 2020
28/01/21	PRICE SENSITIVE	203.68KB	Share
PAB Entitlement Offer Prospectus
09/11/20	PRICE SENSITIVE	390.61KB	Share
PAB $7.3M Capital Raising
09/11/20	PRICE SENSITIVE	147.87KB	Share
PAB Investor Presentation - November 2020 - Updated
05/11/20	PRICE SENSITIVE	11.32MB	Share
PAB Investor Presentation - November 2020
05/11/20	PRICE SENSITIVE	1.46MB	Share
PAB Trading Halt
05/11/20	PRICE SENSITIVE	200.12KB	Share
PAB Appendix 4C - Quarterly - 30 September 2020
26/10/20	PRICE SENSITIVE	237.83KB	Share
PAB Response to ASX Price Query
23/10/20	PRICE SENSITIVE	225.68KB	Share
PAB First patent granted for Deoxymab-nanoparticles
06/10/20	PRICE SENSITIVE	231.93KB	Share
PAB Patrys adds full human antibody to Deoxymab portfolio
28/09/20	PRICE SENSITIVE	276.67KB	Share
PAB Response to ASX Price Query
15/09/20	PRICE SENSITIVE	224.67KB	Share
PAB Appendix 4E and 2020 Annual Report
25/08/20	PRICE SENSITIVE	1.13MB	Share
PAB Appendix 4C - Quarterly - 30 June 2020
30/07/20	PRICE SENSITIVE	237.92KB	Share
PAB Entitlement Offer Prospectus
22/06/20	PRICE SENSITIVE	408.76KB	Share
PAB $4.29 Million Fully Underwritten Rights Issue
22/06/20	PRICE SENSITIVE	138.68KB	Share
PAB Investor Presentation - June 2020
18/06/20	PRICE SENSITIVE	5.14MB	Share
PAB Trading Halt
18/06/20	PRICE SENSITIVE	275.21KB	Share
PAB Appendix 4C - Quarterly - 31 March 2020
27/04/20	PRICE SENSITIVE	223.23KB	Share
PAB PAT-DX1 mechanism for crossing blood brain barrier confirmed
16/03/20	PRICE SENSITIVE	258.28KB	Share
PAB PAT-DX1-NP crosses BBB and targets tumours
02/03/20	PRICE SENSITIVE	229.63KB	Share
PAB Appendix 4D - Half Year Accounts - 31 December 2019
24/02/20	PRICE SENSITIVE	585.47KB	Share
PAB Appendix 4C - Quarterly - 31 December 2019
30/01/20	PRICE SENSITIVE	269.8KB	Share
PAB Patrys Receives R&D Tax Incentive Refund
07/11/19	PRICE SENSITIVE	146.68KB	Share
PAB Appendix 4C - Quarterly - 30 September 2019
29/10/19	PRICE SENSITIVE	278.62KB	Share
PAB Appendix 4E and 2019 Annual Report
23/08/19	PRICE SENSITIVE	1.1MB	Share
PAB Appendix 4C - Quarterly - 30 June 2019
30/07/19	PRICE SENSITIVE	173.33KB	Share
PAB PAT-DX1 significantly improves survival in aggressive GBM
22/07/19	PRICE SENSITIVE	288.63KB	Share
PAB Europe grants patent for Deoxymab 3E10
17/07/19	PRICE SENSITIVE	615.05KB	Share
PAB PAT-DX1 Reduces Brain Metastases, Enhances Radiation Therapy
30/05/19	PRICE SENSITIVE	254.91KB	Share
PAB Appendix 4C - Quarterly - 31 March 2019
24/04/19	PRICE SENSITIVE	235.56KB	Share
PAB Market Update
29/03/19	PRICE SENSITIVE	243.59KB	Share
PAB Appendix 4D - Half Year Accounts - 31 December 2018
20/02/19	PRICE SENSITIVE	487.29KB	Share
PAB Appendix 4C - Quarterly - 31 December 2018
30/01/19	PRICE SENSITIVE	279.89KB	Share
PAB Patrys Receives R&D Tax Incentive Refund
08/01/19	PRICE SENSITIVE	108.29KB	Share
PAB PAT-DX1 Suppresses Breast Cancer Brain Metastases
20/12/18	PRICE SENSITIVE	248.11KB	Share
PAB Appendix 4C - Quarterly - 30 September 2018
31/10/18	PRICE SENSITIVE	233.2KB	Share
PAB Settlement of Manufacturing Claims
25/10/18	PRICE SENSITIVE	102.79KB	Share
PAB PAT-DX1 Clinical Target Indications Confirmed
04/10/18	PRICE SENSITIVE	252.8KB	Share
PAB Patrys and WEHI Awarded Grant
28/08/18	PRICE SENSITIVE	252.24KB	Share
PAB Appendix 4E and 2018 Annual Report
24/08/18	PRICE SENSITIVE	1.1MB	Share
PAB Patent Granted for Pre-clinical IgM Candidate PAT-LM1
01/08/18	PRICE SENSITIVE	710.34KB	Share
PAB Appendix 4C - Quarterly - 30 June 2018
26/07/18	PRICE SENSITIVE	235.01KB	Share
PAB Preliminary PAT-DX1 pharmacokinetics
05/07/18	PRICE SENSITIVE	165.25KB	Share
PAB China and Japan both grant patents for Deoxymab 3E10
03/07/18	PRICE SENSITIVE	140.91KB	Share
PAB PAT-DX1 Targets and Kills Brain Cancer Stem Cells
31/05/18	PRICE SENSITIVE	142.76KB	Share
PAB Patrys Increases Capital Raising to $4.6 million
21/05/18	PRICE SENSITIVE	100.89KB	Share
PAB New Pre-Clinical Collaboration on PAT-DX1
17/05/18	PRICE SENSITIVE	138.9KB	Share
PAB Patrys Completes $3.5M Placement
16/05/18	PRICE SENSITIVE	99.71KB	Share

REFRESH

1 2

(20min delay)
Last 0.9¢		Change 0.000(0.00%)		Mkt cap ! $18.51M

Open	High	Low	Value	Volume
0.9¢	0.9¢	0.9¢	$18.68K	2.075M

Buyers (Bids)

No.	Vol.	Price($)
11	2642383	0.8¢

Sellers (Offers)

Price($)	Vol.	No.
0.9¢	856022	2

View Market Depth

No.	Vol.	Price($)
11	2642383	0.008
17	4746715	0.007
11	2787680	0.006
8	3144992	0.005
5	4324000	0.004

Price($)	Vol.	No.
0.009	856022	2
0.010	1830082	5
0.011	1380000	4
0.012	372407	3
0.013	990000	2

Last trade - 16.10pm 26/04/2024 (20 minute delay)


Last 0.9¢		Change 0.000 ( 0.00 %)
Open	High	Low	Volume
0.9¢	0.9¢	0.9¢	97616
Last updated 11.58am 26/04/2024 ?

PAB (ASX) Chart

PATRYS LIMITED - Announcements

Corporate SpotlightNot Yet Available

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories

Corporate Spotlight
Not Yet Available